TimoD implant

DRUG2 trials

Sponsors

EyeD Pharma

Conditions

GlaucomaOcular HypertensionPrimary Open-angle Glaucoma

Phase 1

Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

TerminatedNCT06321562

EyeD PharmaPrimary Open-angle Glaucoma

Start: 2023-03-01End: 2025-06-26Updated: 2025-07-16

Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery

RecruitingNCT07036510

EyeD PharmaGlaucoma, Ocular Hypertension

Start: 2025-06-12End: 2027-01-01Target: 42Updated: 2026-07-30